FibroGen Q2 loss narrows to $13.7M; China sale to AstraZeneca now ~$210M, cash runway into 2028

KYNTRA BIO, INC.

2025-Q2 EPS reported -$0.73 vs consensus -$2.35 ▲ beat (+69.0%)

Net loss from continuing ops $13.7M ($3.38/sh) vs $47.1M loss ($11.79/sh) in Q2 2024; revenue $1.3M.
Sale of FibroGen China to AstraZeneca now ~$210M total consideration (up $50M), including ~$125M net cash; close expected Q3 2025.
Cash runway extended into 2028 upon China sale close; Q2 consolidated cash $142.1M.
Agreed with FDA on pivotal Phase 3 design for roxadustat in LR-MDS with high transfusion burden; protocol filing Q4 2025.
Phase 2 monotherapy trial of FG-3246 in mCRPC expected to start Q3 2025; combo data from UCSF study expected Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.